VICTRELIS
Total Payments
$3.8M
Transactions
20
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $13,150 | 9 | 0 |
| 2018 | $444,747 | 5 | 0 |
| 2017 | $3.3M | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.8M | 20 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HCV-TARGET Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study | Merck Sharp & Dohme Corporation | $3.7M | 0 |
| The assessment of intrahepatic levels and boceprevir concentrations at the time of liver transplantation in patients receiving boceprevir while on the liver transplant waiting list. | Merck Sharp & Dohme Corporation | $62,393 | 0 |
| A Phase 2, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis C | Merck Sharp & Dohme Corporation | $10,400 | 0 |
| A Phase 3, Safety and Efficacy Study of Boceprevir,Peginterferon Alfa-2a,ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects Protocol No. P07755 also known as MK-3034-040-00 | Merck Sharp & Dohme Corporation | $2,750 | 0 |
Top Doctors Receiving Payments for VICTRELIS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $3.8M | 20 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.8M
- Total Doctors 0
- Transactions 20
About VICTRELIS
VICTRELIS is a drug associated with $3.8M in payments to 0 healthcare providers, recorded across 20 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $13,150 was paid across 9 transactions to 0 doctors.
The most common payment nature for VICTRELIS is "Unspecified" ($3.8M, 100.0% of total).
VICTRELIS is associated with 4 research studies, including "HCV-TARGET Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study" ($3.7M).